Solventum went ahead and shared on December 23, 2025, that it has accomplished its acquisition of Acera Surgical.
It is worth noting that in November, the spinoff from 3M Health Care announced an agreement to go ahead and buy Acera Surgical, which is a developer of soft tissue repair treatments, for almost $900 million. The deal goes on to include a $725 million cash payment, in addition to $125 million in terms of contingent cash payments that are based upon future milestones.
Acera Surgical is involved in developing innovative synthetic alternatives when it comes to soft tissue repair by way of using a platform based on proprietary electrospinning technology. The Restrata products of the company treat hard-to-heal, pretty intricate wounds within acute care settings. It at present goes on to offer Restrata in the U.S.
Solventum said that the innovation engine and commercial footprint of Acera indeed sync with its leadership within advanced wound care. It looks to make use of its relationships and go-to-market capacities in order to speed up the adoption of Restrata products within the acute care market. Solventum – spinoff from 3M Health Care also hopes to go ahead and generate synergies by way of leveraging its own international footprint.
The company anticipates making use of its specialized wound care sales force as well as leadership when it comes to negative pressure wound therapy in order to support Restrata.
Solventum anticipates Acera to go ahead and generate almost $90 million in sales in 2025. It indeed expects a slightly dilutive effect on a letter’s earnings per share – EPS in 2026 and then an accretive one in 2027. The company also looks to use cash on hand in order to finance the deal, which it anticipates to close in the first half of 2026.
The CEO of Solventum, Bryan Hanson, remarked that announcing and completing their first strategic acquisition is indeed a major milestone and the successful completion of yet another commitment that is made as part of their three-phased transition plan. The addition of innovative synthetic tissue matrix technology from Acera goes on to complement their present advanced wound care portfolio, thereby elevating the solutions their specialized commercial team can offer to clinicians as well as decision makers when it comes to acute care settings. He added that they are excited to go ahead and welcome the Acera team to the Solventum family and also look forward to their work together in order to speed up the growth and also create major value for patients along with clinicians and, of course, shareholders.